EscharEx is an enzyme commercialized by MediWound, with a leading Phase II program in Venous Leg Ulcers (Crural Ulcer). According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of EscharEx’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Related Company Profiles

View all

The revenue for EscharEx is expected to reach an annual total of $5 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

EscharEx Overview

EscharEx is under development for the debridement of chronic and other hard to heal venous leg ulcers, diabetic foot ulcers (lower extremity), traumatic/post operative wounds. It is applied topically. The drug candidate is a proteolytic enzyme. The development of the drug candidate is based on proteolytic enzymatic technology.

See Also:

MediWound Overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MediWound is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
The company reported revenues of (US Dollars) US$26.5 million for the fiscal year ended December 2022 (FY2022), an increase of 11.5% over FY2021. The operating loss of the company was US$8.4 million in FY2022, compared to an operating loss of US$11.2 million in FY2021. The net loss of the company was US$19.6 million in FY2022, compared to a net loss of US$13.6 million in FY2021. The company reported revenues of US$4.8 million for the second quarter ended June 2023, an increase of 25.6% over the previous quarter.

For a complete picture of EscharEx’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.